This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL Society gives CLL patients’ voices many opportunities to be heard through patient quotes, stories, testimonials, and much more. Please see below to learn how easy it is for you to contribute in making Blood Cancer Awareness month ring with the voices of our CLL community. We invite you to write something for this campaign. The world will hear us! Thank you.
Blood Cancer Awareness Month
Send us your quotes! September is Blood Cancer Awareness Month. Throughout the month, CLL Society will be active on social media to raise awareness and increase education for all impacted by CLL. As part of this effort, we want to elevate your voices. If you would like to provide a personal quote or story for CLL Society to post on our Facebook and/or Twitter please click here.
CLL Society invites you to attend our August 26th webinar featuring Dr. Ian Flinn. Have you relapsed on, or become refractory to a BTKi drug such as ibrutinib, or the BCL-2i venetoclax? These drugs have radically improved how CLL is treated. However, when patients relapse or become refractory to these treatments, the approved PI3 kinase inhibitors duvelisib or idelalisib, and the still experimental umbralisib, offer a potent and potentially helpful third option. Side effects of PI3Ks have made some patients apprehensive. However, if properly managed, many CLL patients could reap benefits from these effective medications. Frontload your knowledge about PI3K inhibitors! Join us on August 26th for Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? Send your questions in advance of the webinar by emailing email@example.com.
Do you want to brush up on your knowledge before the PI3K webinar? A second look at our previously published articles on this topic might help you to follow along or come up with questions.
- Things to Know About Idelalisib
- ASH 2019: Dr. Pagel Discusses Intermittent Dosing of PI3K Inhibitor ME401 in CLL
- ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for CLL
- ASH 2017: Dr. Brander on Umbralisib (TGR-1202) in CLL
3rd COVID-19 Vaccine Dose Approved for CLL Patients
The FDA has announced the expanded Emergency Use Authorization (EUA) for a third booster dose of the Moderna or Pfizer vaccine for the immune compromised, including chronic lymphocytic leukemia (CLL) patients. Please learn more here.
CLL Society brings you the following special article announcing that the Shingrix vaccine is approved in the US for the prevention of shingles in immunocompromised adults. Please learn more here.
The Leukemia & Lymphoma Society is offering financial assistance of up to $8,000 for CLL patients through the Co-Pay Assistance Program for treatment-related expenses for U.S. patients, whether you are in active treatment, being monitored for watch and wait, or in follow up care. Find out if you qualify and how to apply, funding is limited.
LRF invites you to participate in a confidential survey as part of their effort to gauge COVID-19 impact on the lymphoma community. LRF’s aim is to better understand the implications of COVID-19 so that they may develop appropriate programs and materials for patient education and awareness purposes. You can find this survey and more on our Survey Central page.
CLL Society has partnered with Clinical Care Options to develop an educational activity for healthcare providers who treat patients with CLL. This program features expert insight commentaries, an Interactive Treatment Decision Support Tool, and a series of micro education modules. Not only will it help improve CLL care for healthcare providers, it can also help empower and engage patients to become informed participants in shared decision-making. Learn more about “Optimizing Decision-Making in CLL in an Era of Novel Agents” and consider sharing with your healthcare providers.
The 1-hour online educational session, Navigating Treatment with BTK Inhibitors led by Dr. Matthew Davids, Associate Professor of Medicine, Harvard Medical School, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute is now available to watch on-demand. Hear a CLL patient’s perspective on the latest findings on long-term efficacy of BTK inhibitors, side-effect management, and adopting healthy lifestyles to improve outcomes.
This educational module is the first in a series specifically designed to help patients and caregivers understand the available treatment options for CLL across the continuum of care, learn about the details of BTK inhibitor treatments, and confidently talk with your doctors and other clinicians to align your goals and priorities for care.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.